Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;100(8):1408-1422.
doi: 10.1002/ajh.27737. Epub 2025 Jun 17.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management

Shai Shimony  1 , Marlise R Luskin  1 , Naseema Gangat  2 , Nicole R LeBoeuf  3   4 , Angela M Feraco  5   6 , Andrew A Lane  1
Affiliations
Review

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management

Shai Shimony et al. Am J Hematol. 2025 Aug.

Abstract

Overview: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic neoplasm that involves multiple organs, including the skin, bone marrow and blood, lymph nodes, and central nervous system. Violaceous tumors or plaques appearing in sun-exposed areas are characteristic and present in most patients. The disease typically affects adult men aged 60-70 years, although children and younger adults may also be affected.

Diagnosis: Diagnosis is based on biopsy of an involved site and is typically based on the identification of blastoid cells displaying the classical immunophenotypes CD123, CD4, and CD56 in addition to specific pDC markers.

Prognosis: The median overall survival is 18-24 months. Potential risk factors for shortened survival include older age, overt bone marrow involvement, and genetic abnormalities.

Therapy and management: Either chemotherapy-based regimens or tagraxofusp, a CD123-directed interleukin 3 conjugated with diphtheria toxin, may be used for upfront therapy. Eligible patients are recommended to be consolidated with hematopoietic allogeneic stem cell transplantation. Assessment and treatment of the central nervous system is mandatory, and careful monitoring of skin disease in conjunction with dermatology is essential.

Keywords: BPDCN; diagnostic criteria; tagraxofusp.

PubMed Disclaimer

References

    1. G. S. Guru Murthy, N. Pemmaraju, and E. Atallah, “Epidemiology and Survival of Blastic Plasmacytoid Dendritic Cell Neoplasm,” Leukemia Research 73 (2018): 21–23, https://doi.org/10.1016/j.leukres.2018.08.014.
    1. M. J. Kim, A. Nasr, B. Kabir, et al., “Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review,” Journal of Pediatric Hematology/Oncology 39, no. 7 (2017): 528–537, https://doi.org/10.1097/MPH.0000000000000964.
    1. B. Cuglievan, J. Connors, J. He, et al., “Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review in Pediatrics, Adolescents, and Young Adults (AYA) and an Update of Novel Therapies,” Leukemia 37, no. 9 (2023): 1767–1778, https://doi.org/10.1038/s41375‐023‐01968‐z.
    1. J. Taylor, M. Haddadin, V. A. Upadhyay, et al., “Multicenter Analysis of Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm Offers a Pretargeted Therapy Benchmark,” Blood 134, no. 8 (2019): 678–687, https://doi.org/10.1182/blood.2019001144.
    1. K. Laribi, A. Baugier de Materre, M. Sobh, et al., “Blastic Plasmacytoid Dendritic Cell Neoplasms: Results of an International Survey on 398 Adult Patients,” Blood Advances 4, no. 19 (2020): 4838–4848, https://doi.org/10.1182/bloodadvances.2020002474.